Results 91 to 100 of about 6,396 (177)

Deferiprone for the treatment of Friedreich's ataxia.

, 2013
Friedreich's ataxia (FRDA) is a neurological disease related to a deficiency of the protein frataxin involved in iron-sulfur (Fe-S) cluster biogenesis.
Pandolfo, Massimo, Hausmann, Laura
core   +1 more source

Deferiprone: new environmental perspectives. Insights into its sequestering ability vs. different metal cations

Ecotoxicology and Environmental Safety
Deferiprone, generally, is considered an important chelating agent for Fe3+ overload. From a literature data analysis, a lack of information on the interaction of this molecule toward a series of metal cations emerged, inducing to fill out the topic. The
Anna Irto, Francesco Crea, Marco Milone, Giuseppe Gattuso, Clemente Bretti, Concetta De Stefano, Rosalia Maria Cigala   +6 more
doaj   +1 more source

Lasting off-drug antiretroviral activity by deferiprone in isolate-infected, long-term replenished primary cell cultures.

, 2016
Long-term replenished primary cell cultures were infected with isolate #990,010 on Day 0 as described [43] and replenished as indicated by arrowheads; on each occasion, half of the culture was replaced.
Myung Hee Park (176990), Bernadette M. Cracchiolo (462186), Paul E. Palumbo (462178), Michael Spino (462182), John Connelly (462188), Bart Holland (462191), Tsafi Pe’ery (462192), Axel-Rainer Hanauske (462179), Jonathan Karn (220557), Hartmut M. Hanauske-Abel (462176), Deepti Saxena (462177), Michael B. Mathews (35045), Fernando Tricta (462187), Darlene D’Alliessi Gandolfi (2793712)   +13 more
core   +1 more source

Solubility of Deferiprone in Non-Aqueous Mixtures of Polyethylene Glycol 400 and 1-Propanol at 293.2–323.2 K

Liquids
Utilizing the shake-flask technique under atmospheric pressure (101 kPa) within the temperature range of 293.2 to 313.2 K, the experimental solubility and density values of deferiprone were determined in binary mixtures of polyethylene glycol 400 and 1 ...
Homa Rezaei, Abolghasem Jouyban
doaj   +1 more source

MODIFIED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING DEFERIPRONE

The disclosure is directed to pharmaceutical compositions for oral administration comprising deferiprone. In particular, the disclosure is also directed to modified release tablets suitable either for twice daily administration or once daily ...
Andrea Gazzaniga, Micol Cirilli, Marisa Pertile, Matteo Cerea   +3 more
core   +2 more sources

Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis

, 2006
Most deaths in beta-thalassemia major result from cardiac complications due to iron overload. Differential effects on myocardial siderosis may exist between different chelators.
Gotsis, ED, Karagiorga, M, Berdoukas, V, Aessopos, A, Tanner, MA, Galanello, R, Pennell, DJ, Piga, A, Smith, GC, Westwood, MA, Ladis, V, Wonke, B   +11 more
core  

Assessment of the Effect of the Oral Iron Chelator Deferiprone on Asymptomatic Plasmodium Falciparum Parasitemia in Humans [PDF]

, 1998
While the parenteral iron-chelating agent desferrioxamine B has anti- malarial activity in humans, the usefulness of an orally active chelator for this indication has not been investigated previously in vivo.
Thuma, Philip, Zulu, S., Fassos, F. F., Koren, G., Brittenham, G. M., Olivieri, N. F., Mabeza, G. F., Parry, D., Biemba, G., Mcclelland, R. A., Gordeuk, V. R.   +10 more
core  

Iron Chelation Therapy in Iron Overload Disorders: A Systematic Review with Narrative Synthesis of Bioenergetic Dysfunction, Oxidative Stress, and Biomarker-Guided Management. [PDF]

Int J Mol Sci
Alburayh KAS, Emara AM, Elgharabawy RM.
europepmc   +1 more source

Sph-mediated mtDNA release and autophagy-dependent ferroptosis contribute to Staphylococcus aureus-induced mastitis. [PDF]

PLoS Pathog
Wei Y, Zhao X, Yin Z, Zhang Y, Zhai Y, Zhan B, Wang Y, He J, Wang J, Deng X, Xu L, Feng H.   +11 more
europepmc   +1 more source

Medication Adherence, Clinical Outcomes, and Health-Related Quality of Life Among Pediatric Patients with β-Thalassemia Major Receiving Iron Chelation Therapy: A Multicenter Study from Punjab, Pakistan. [PDF]

Patient Prefer Adherence
Muneeb A, Inam S, Ali I, Alshehri AA, Siddiq M, Ali S.   +5 more
europepmc   +1 more source